Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK14 | O94921 | 8/20 | 0.52 |
| ▸ | CCNY | Q8ND76 | 8/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | ABL1 | P00519 | 1/20 | 0.40 |
| ▸ | SRC | P12931 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | JAK2 | O60674 | 2/20 | 0.39 |
| ▸ | TYK2 | P29597 | 2/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | JAK1 | P23458 | 1/20 | 0.39 |
| ▸ | TRPV1 | Q8NER1 | 4/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8261466 | 0.91 | CDK14 (0.54) | CDK14CCNYPOLBSMN1; SMN2ABL1 | |
| SCHEMBL959301 | 0.87 | POLB (0.56) | CDK14CCNYPOLBSMN1; SMN2ABL1 | |
| SCHEMBL954966 | 0.84 | CDK14 (0.55) | CDK14CCNYABL1SRCHPGD | |
| SCHEMBL13993632 | 0.83 | CDK14 (0.56) | CDK14CCNYPOLBABL1SRC | |
| SCHEMBL957511 | 0.83 | CDK14 (0.54) | CDK14CCNYABL1SRCHPGD | |
| SCHEMBL16995305 | 0.81 | POLB (0.52) | CDK14CCNYPOLBSMN1; SMN2JAK1 | |
| SCHEMBL13993605 | 0.81 | CDK14 (0.47) | CDK14CCNY | |
| SCHEMBL22235847 | 0.80 | MEN1 (0.42) | — | |
| SCHEMBL8261470 | 0.79 | CDK14 (0.53) | CDK14CCNYPOLBSMN1; SMN2ABL1 | |
| SCHEMBL1286749 | 0.78 | CDK14 (0.53) | CDK14CCNYJAK2TYK2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080306069-A1 | Pyrazole Derivatives for the Inhibition of CDK'S and GSK'S | ASTEX THERAPEUTICS LIMITED (UK) | 2008-12-11 | — | — | US | disclosed |
| US-20080306069-A1 | Pyrazole Derivatives for the Inhibition of CDK'S and GSK'S | ASTEX THERAPEUTICS LIMITED (UK) | 2008-12-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080306069-A1 | Pyrazole Derivatives for the Inhibition of CDK'S and GSK'S | GSK3A, CDK11A, CDK1 | CDK14 8/4885CCNY 51/4885POLB 1022/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.